Trial · NCT00584948

Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome

NCT00584948, Not applicable, Completed, University of California, Davis; results first posted 2017-04-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome. Trials, record NCT00584948. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00584948

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome
NCT number: NCT00584948
Status: Completed
Phases: Not applicable
Enrollment: 94 participants, actual
Lead sponsor: University of California, Davis
Conditions: Fragile X-Associated Tremor/Ataxia Syndrome, Fragile X Premutation Carriers
Interventions: Memantine, Placebo
First posted: 2008-01-02
Last updated: 2017-05-30
Results first posted: 2017-04-10

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II)	One Year	The BDS-II is a 9-item, 27-point instrument that measures executive function as the capacity for behavioral and attentional self-regulation. Total score is a sum of the 9 items, with a range of 0-27, in which a higher score indicates a better performance.
Primary	Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale	1 year	The CATSYS is a set of computer assisted diagnostic instruments that can measure intention tremor, postural tremor, postural sway, manual coordination and reaction time. The tremor intensity is defined as the root mean square of accelerations, recorded in the 0.9 Hz to 15.0 Hz band during the test period. Unit is measured in m/s2

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II)	One Year		units on a scale	MEAN
PRIMARY	Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale	1 year		m/s^2	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II)	Memantine	Baseline	17.44	Standard Deviation 5.19	units on a scale
Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II)	Placebo	Baseline	16.12	Standard Deviation 5.43	units on a scale
Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II)	Memantine	One Year	15.66	Standard Deviation 4.11	units on a scale
Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II)	Placebo	One Year	15.72	Standard Deviation 3.93	units on a scale
Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale	Memantine	Baseline	1.31	Standard Deviation 1.02	m/s^2
Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale	Placebo	Baseline	1.05	Standard Deviation 0.73	m/s^2
Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale	Memantine	One Year	1.77	Standard Deviation 1.78	m/s^2
Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale	Placebo	One Year	1.89	Standard Deviation 2.19	m/s^2

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Memantine	47
Overall Study	STARTED	Placebo	47
Overall Study	COMPLETED	Memantine	34
Overall Study	COMPLETED	Placebo	36
Overall Study	NOT COMPLETED	Memantine	13
Overall Study	NOT COMPLETED	Placebo	11

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Constipation	Gastrointestinal disorders	Memantine	6	47	10
other	Constipation	Gastrointestinal disorders	Placebo	2	47	4
serious	Motor Vehicle Accident	Musculoskeletal and connective tissue disorders	Memantine	1	47	1
serious	Motor Vehicle Accident	Musculoskeletal and connective tissue disorders	Placebo	0	47	0
serious	Lung Cancer	Respiratory, thoracic and mediastinal disorders	Memantine	1	47	1
serious	Lung Cancer	Respiratory, thoracic and mediastinal disorders	Placebo	0	47	0
serious	Ovarian Cancer	Reproductive system and breast disorders	Memantine	0	47	0
serious	Ovarian Cancer	Reproductive system and breast disorders	Placebo	1	47	1
serious	Pneumonia	Respiratory, thoracic and mediastinal disorders	Memantine	0	47	0
serious	Pneumonia	Respiratory, thoracic and mediastinal disorders	Placebo	1	47	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Memantine
Total, all-cause mortality	Placebo
Total, other adverse events	Memantine	6	47
Total, other adverse events	Placebo	2	47
Total, serious adverse events	Memantine	2	47
Total, serious adverse events	Placebo	3	47

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
24345444	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
RL1AG032115	Characterization and Treatment of CNS Abnormalities in Premutation Carriers (4 of	HAGERMAN, RANDI J.	UNIVERSITY OF CALIFORNIA AT DAVIS	NATIONAL INSTITUTE ON AGING	2007 to 2011

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Memantine vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00584948

GET https://conductscience.org/api/trials/v1/NCT00584948/registered

API reference For AI assistants